The National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination (FAD) recommending the combination of Bristol-Myers Squibb’s Opdivo® (nivolumab) plus Yervoy® (ipilimumab) to treat NHS patients in England with an advanced form of the most common type of kidney cancer, renal cell carcinoma (RCC).
This recommendation signifies an important landmark in the treatment landscape, representing the first approval of an Immuno-Oncology (I-O) combination therapy for first-line patients with this type of cancer in England.
I-O works by stimulating the body’s immune system to recognise and eliminate cancer cells. Nivolumab and ipilimumab will be immediately available on the Cancer Drugs Fund (CDF) as a first-line treatment option for previously-untreated intermediate- and poor-prognostic risk* advanced RCC, and could be a treatment option for up to 1700 patients each year in England.
RCC is currently the seventh most common cancer and rates have risen by 47% over the last decade or so in the UK, which is faster than most other common cancers, including lung and bowel cancer.
In 2015, more than 12,500 people were diagnosed with kidney cancer in the UK and around 4500 people die from the disease each year. This represents an average of 12 people every day.
In England specifically, around one in four cases of kidney cancer (25% – 31%) are diagnosed when the patient is already at an advanced stage. Of those patients
diagnosed at the most advanced stage, stage IV, approximately only 5% will survive their cancer for five years or more.
Rose Woodward, co-founder of the Kidney Cancer Support Network, said: “Kidney cancer is a devastating disease and at the most advanced stage prognosis is poor. Having access to this combination therapy on the NHS is therefore an important new addition and a vital step in our fight to extend survival.”
Dr Paul Nathan, Consultant Medical Oncologist at Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust, said: “It’s very good news that the combination of nivolumab and ipilimumab has now been approved for use in patients with intermediate- and poor risk advanced renal cell carcinoma.
“A study has demonstrated that this
immunotherapy combination is superior to sunitinib in extending overall survival and may now benefit patients whose lives are threatened by a cancer that has increased in incidence by nearly 50% in the last decade.”